Cutaneous T-Cell Lymphoma (CTCL) Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, Key Companies

March 15 12:26 2023
Cutaneous T-Cell Lymphoma (CTCL) Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 25+ key pharma and biotech companies are working on 27+ pipeline drugs in the Cutaneous T-Cell Lymphoma (CTCL) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

As per the DelveInsight estimates, the dynamics of the Cutaneous T-cell Lymphoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world, and expected launch of emerging therapies in the market.

The CTCL pipeline possesses multiple potential drugs in late- and mid-stage developments to be launched shortly. Some of the key companies in the market include Soligenix, Citius Pharma, Medivir AB, Merck Sharp & Dohme, Bioniz Therapeutics, BeiGene, Codiak BioSciences, Philogen, Astex Pharmaceuticals, and others.

Cutaneous T-Cell Lymphoma (CTCL) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Cutaneous T-Cell Lymphoma Market. 

The Cutaneous T-Cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Cutaneous T-Cell Lymphoma Pipeline Analysis

Cutaneous T-Cell Lymphoma (CTCL) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Cutaneous T-Cell Lymphoma and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Cutaneous T-Cell Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Cutaneous T-Cell Lymphoma Therapeutic Segment @

Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Landscape

CTCL has an active pipeline as many pharmaceutical companies are working towards developing effective and affordable therapy. There are approx. 25+ key companies are developing therapies for Cutaneous T-Cell Lymphoma. Currently, Soligenix is leading the therapeutics market with its Cutaneous T-Cell Lymphoma drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Include:

4SC, Bio-Path Holdings, BioInvent International AB, Bioniz Therapeutics, Citius Pharmaceuticals, Codiak BioSciences, Elorac, Equillium, Genzada Pharmaceuticals, Hoffmann-La Roche, Innate Pharma, Jiangsu Simcere Pharmaceutical, Kymera Therapeutics, Legend Biotech, Merck Sharp & Dohme LLC, miRagen Therapeutics, Myeloid Therapeutics, Otsuka Pharmaceutical, Scopus BioPharma, Soligenix, Sorrento Therapeutics, VidacPharma, Viridian Therapeutics, and many others.

Cutaneous T-Cell Lymphoma (CTCL) Emerging and Marketed Drugs Covered in the Report Include:

  • Adcetris (Brentuximab Vedotin): Seagen

  • ASTX660: Astex Pharmaceuticals

  • Bifikafusp alfa + onfekafusp alfa: Philogen

  • BNZ-1: Bioniz Therapeutics

  • exoIL-12: Codiak BioSciences

  • HyBryte (SGX301): Soligenix

  • I/ONTAK (E7777): Citius Pharmaceuticals

  • Lacutamab (IPH4102): Innate Pharma

  • Pembrolizumab: Merck Sharp & Dohme

  • Potelegio (Mogamulizumab-kpkc): Kyowa Hakko Kirin

  • Remetinostat: Medivir AB

  • Resminostat: 4SC AG

  • SGX301: Soligenix

  • Targretin (Bexarotene): Valeant Pharmaceuticals/ Bausch Health

  • Tislelizumab: BeiGene

  • Uvadex (Methoxsalen): Mallinckrodt Pharmaceuticals

  • Valchlor/Ledaga (Mechlorethamine): Helsinn Therapeutics

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Cutaneous T-Cell Lymphoma Current Treatment Patterns

4. Cutaneous T-Cell Lymphoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Cutaneous T-Cell Lymphoma Late-Stage Products (Phase-III)

7. Cutaneous T-Cell Lymphoma Mid-Stage Products (Phase-II)

8. Cutaneous T-Cell Lymphoma Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Cutaneous T-Cell Lymphoma Discontinued Products

13. Cutaneous T-Cell Lymphoma Product Profiles

14. Key Companies in the Cutaneous T-Cell Lymphoma Market

15. Key Products in the Cutaneous T-Cell Lymphoma Therapeutics Segment

16. Dormant and Discontinued Products

17. Cutaneous T-Cell Lymphoma Unmet Needs

18. Cutaneous T-Cell Lymphoma Future Perspectives

19. Cutaneous T-Cell Lymphoma Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Strategies


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States